Bloomberg has a nice piece documenting a number of instances in which drug companies have promoted their drugs for uses not approved by the Food and Drug Administration and it harmed or killed patients. The part missing from this discussion is any discussion of the perverse incentives that patent monopolies create for promoting off-label uses. This is a strong argument for using alternative methods for financing research. By contrast, the article indicates that we have to hope that: "that drug companies actually honor the promises they keep making."
The American Prospect is nonprofit, reader-funded journalism—and we need your help.
Our reporters dig deep, hold power to account, and explain how policy shapes people’s lives. If you value independent journalism that goes beyond the headlines, now’s the time to support it.
Here’s how you can help: • Donate to power fearless reporting
• Subscribe to get our print magazine 6x/year.
